King’s College London will be the site of Phase 2 trials of Lightlake Therapeutics’s opioid antagonist-based nasal spray treatment for bulimia nervosa, the company has announced. Lightlake currently has Phase 2 trials underway in Finland to demonstrate the effectiveness of its naloxone nasal spray for the treatment of binge eating disorder in overweight and obese patients.
Lightlake CEO Roger Crystal said of the new trials: “We are very pleased to be working with King’s and to have two remarkable people from the institution sponsoring our Phase II trials. Professor Janet Treasure, head of the Eating Disorders Unit at the South London and Maudsley NHS Trust and the author of several well-regarded books on eating disorders, and Professor Ulrike Schmidt, a consultant psychiatrist for the Eating Disorders Service and a fellow of the Academy for Eating Disorders, will be tremendous guides for our Phase II trials. It is an absolute privilege to work with them and King’s in general, and we look forward to coming to the institution early next year to test a product that has the potential to improve the lives of so many people.”
Read the Lightlake press release.
